All In Biotech

Drug Trial Radar · NCT01568866

Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients

A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma

Last checked: Nov 20, 2026Latest source record: Nov 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 929 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

929

Actual

Start

Jun 20, 2012

Primary completion

Nov 10, 2014

Study completion Feb 5, 2018

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Apr 2, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study was to compare progression-free survival in patients with multiple myeloma who relapsed after 1 to 3 prior therapies treated with carfilzomib plus dexamethasone or bortezomib plus dexamethasone.

Conditions

  • Multiple Myeloma

Interventions

  • CarfilzomibDrug

    Carfilzomib is administered over 30 minutes as an infusion.

  • BortezomibDrug

    Bortezomib is administered as a 3-5 second bolus IV injection or SC injection (in accordance with regulatory approval)

  • DexamethasoneDrug

    Tablet for oral administration; On days when carfilzomib or bortezomib was administered, the dexamethasone was to be given 30 minutes to 4 hours prior to the carfilzomib or bortezomib dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free SurvivalTime frame: From randomization until the data cut-off date of 10 November 2014; median follow-up time for PFS was 11.1.and 11.9 months in the bortezomib and carfilzomib arms respectively

Locations

241 sites in 27 countries. Site status is shown where the registry gives one.

  • Providence St. Joseph Medical Center

    Burbank, California

  • UCSD Moore Cancer Center

    La Jolla, California

  • UCLA Medical Center

    Los Angeles, California

  • Central Coast Medical Oncology Group

    Santa Maria, California

  • Colorado Blood Cancer Institute

    Denver, Colorado

  • MAB Oncology/Hematology

    Melbourne, Florida

  • Palm Beach Cancer Institute

    West Palm Beach, Florida

  • Winship Cancer Institute

    Atlanta, Georgia

  • Hematology Oncology of Indiana, PC

    Indianapolis, Indiana

  • Center for Cancer and Blood Disorders

    Bethesda, Maryland

  • Associates in Oncology/Hematology PC

    Rockville, Maryland

  • University of Michigan

    Ann Arbor, Michigan

  • University of Kansas

    Kansas City, Missouri

  • Hackensack University Medical Ctr

    Hackensack, New Jersey

  • Clinical Research Alliance Inc.

    New York, New York

  • Weill Cornell Medical College

    New York, New York

  • Montefiore Medical Center

    The Bronx, New York

  • Wake Forest University Health Sciences, Section on Hematology and Oncology

    Winston-Salem, North Carolina

  • Gabrail Cancer Center

    Canton, Ohio

  • The Christ Hospital

    Cincinnati, Ohio

  • Western Pennsylvania Hospital

    Pittsburgh, Pennsylvania

  • Hematology/Oncology Associates of SC

    Greenville, South Carolina

  • Vanderbilt Ingram Cancer Center

    Nashville, Tennessee

  • MD Anderson

    Houston, Texas

  • The Methodist Cancer Center

    Houston, Texas

  • Scott & White Memorial Hospital

    Temple, Texas

  • University of Utah School of Medicine

    Salt Lake City, Utah

  • Royal Prince Alfred Hospital

    Camperdown, New South Wales, Australia

  • St. Vincent's Public Hospital Sydney

    Darlinghurst, New South Wales, Australia

  • Saint George Hospital

    Kogarah, New South Wales, Australia

  • Liverpool Hospital

    Liverpool, New South Wales, Australia

  • Royal North Shore Hospital

    Saint Leonards, New South Wales, Australia

  • Calvary Mater Newcastle

    Waratah, New South Wales, Australia

  • Westmead Hospital

    Westmead, New South Wales, Australia

  • Royal Brisbane and Women's Hospital

    Herston, Queensland, Australia

  • Haematology & Oncology Clinics of Australia

    South Brisbane, Queensland, Australia

  • Haematology and Oncology Clinics of Australia at Chermside

    South Brisbane, Queensland, Australia

  • Haematology and Oncology Clinics of Australia at Wesley

    South Brisbane, Queensland, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • The Queen Elizabeth Hospital

    Woodville, South Australia, Australia

Showing 40 of 241 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.